| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia.
|
PLoS Med
|
2008
|
6.61
|
|
2
|
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment.
|
PLoS One
|
2009
|
5.81
|
|
3
|
A long neglected world malaria map: Plasmodium vivax endemicity in 2010.
|
PLoS Negl Trop Dis
|
2012
|
5.24
|
|
4
|
The pathophysiology of vivax malaria.
|
Trends Parasitol
|
2009
|
4.57
|
|
5
|
In vivo parasitological measures of artemisinin susceptibility.
|
J Infect Dis
|
2010
|
4.25
|
|
6
|
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria.
|
J Exp Med
|
2007
|
3.13
|
|
7
|
Artemisinin combination therapy for vivax malaria.
|
Lancet Infect Dis
|
2010
|
3.08
|
|
8
|
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation.
|
J Infect Dis
|
2007
|
3.02
|
|
9
|
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic.
|
Clin Infect Dis
|
2008
|
3.01
|
|
10
|
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria.
|
Proc Natl Acad Sci U S A
|
2008
|
2.80
|
|
11
|
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms.
|
PLoS One
|
2007
|
2.66
|
|
12
|
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.
|
Malar J
|
2009
|
2.64
|
|
13
|
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.
|
Malar J
|
2007
|
2.30
|
|
14
|
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.
|
Clin Infect Dis
|
2011
|
2.16
|
|
15
|
Vivax malaria: a major cause of morbidity in early infancy.
|
Clin Infect Dis
|
2009
|
2.15
|
|
16
|
Plasmodium vivax: clinical spectrum, risk factors and pathogenesis.
|
Adv Parasitol
|
2012
|
1.95
|
|
17
|
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria.
|
J Infect Dis
|
2009
|
1.86
|
|
18
|
The anaemia of Plasmodium vivax malaria.
|
Malar J
|
2012
|
1.82
|
|
19
|
Simplified antimalarial therapeutic monitoring: using the day-7 drug level?
|
Trends Parasitol
|
2008
|
1.70
|
|
20
|
Inferred relatedness and heritability in malaria parasites.
|
Proc Biol Sci
|
2010
|
1.69
|
|
21
|
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity.
|
Malar J
|
2008
|
1.69
|
|
22
|
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.
|
Clin Infect Dis
|
2011
|
1.64
|
|
23
|
Primaquine radical cure of Plasmodium vivax: a critical review of the literature.
|
Malar J
|
2012
|
1.61
|
|
24
|
Plasmodium vivax trophozoites insensitive to chloroquine.
|
Malar J
|
2008
|
1.54
|
|
25
|
A simple score to predict the outcome of severe malaria in adults.
|
Clin Infect Dis
|
2010
|
1.54
|
|
26
|
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
|
Am J Trop Med Hyg
|
2014
|
1.51
|
|
27
|
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand.
|
J Infect Dis
|
2006
|
1.49
|
|
28
|
The global public health significance of Plasmodium vivax.
|
Adv Parasitol
|
2012
|
1.46
|
|
29
|
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria.
|
PLoS Pathog
|
2009
|
1.46
|
|
30
|
High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions.
|
J Infect Dis
|
2009
|
1.40
|
|
31
|
Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome.
|
PLoS Pathog
|
2010
|
1.37
|
|
32
|
Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum.
|
Malar J
|
2007
|
1.35
|
|
33
|
Considerations on the use of nucleic acid-based amplification for malaria parasite detection.
|
Malar J
|
2011
|
1.32
|
|
34
|
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses.
|
J Infect Dis
|
2008
|
1.28
|
|
35
|
Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations.
|
J Infect Dis
|
2008
|
1.26
|
|
36
|
Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia.
|
PLoS Negl Trop Dis
|
2011
|
1.23
|
|
37
|
L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial.
|
PLoS One
|
2013
|
1.20
|
|
38
|
Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria.
|
Am J Trop Med Hyg
|
2007
|
1.20
|
|
39
|
Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria.
|
J Infect Dis
|
2012
|
1.15
|
|
40
|
Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in papua, Indonesia.
|
J Infect Dis
|
2005
|
1.14
|
|
41
|
Early parasitological response following artemisinin-containing regimens: a critical review of the literature.
|
Malar J
|
2013
|
1.14
|
|
42
|
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.
|
Malar J
|
2012
|
1.11
|
|
43
|
Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia.
|
J Infect Dis
|
2010
|
1.11
|
|
44
|
Improving case definitions for severe malaria.
|
PLoS Med
|
2007
|
1.09
|
|
45
|
Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.
|
Antimicrob Agents Chemother
|
2012
|
1.09
|
|
46
|
Diagnosis and treatment of Plasmodium vivax malaria.
|
Adv Parasitol
|
2012
|
1.05
|
|
47
|
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax.
|
J Infect Dis
|
2013
|
1.03
|
|
48
|
A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics.
|
PLoS One
|
2013
|
1.02
|
|
49
|
Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria.
|
Malar J
|
2014
|
1.01
|
|
50
|
Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data.
|
BMC Med
|
2015
|
0.99
|
|
51
|
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
|
Antimicrob Agents Chemother
|
2010
|
0.99
|
|
52
|
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.
|
BMC Med
|
2015
|
0.99
|
|
53
|
Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing.
|
PLoS One
|
2013
|
0.98
|
|
54
|
The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study.
|
BMC Infect Dis
|
2010
|
0.98
|
|
55
|
Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria.
|
Adv Parasitol
|
2012
|
0.97
|
|
56
|
Improving the availability of artesunate for treatment of severe malaria.
|
Med J Aust
|
2006
|
0.96
|
|
57
|
Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.
|
Antimicrob Agents Chemother
|
2011
|
0.96
|
|
58
|
Potential of artemisinin-based combination therapies to block malaria transmission.
|
J Infect Dis
|
2013
|
0.92
|
|
59
|
Safety profile of L-arginine infusion in moderately severe falciparum malaria.
|
PLoS One
|
2008
|
0.92
|
|
60
|
Antimalarial therapies in children from Papua New Guinea.
|
N Engl J Med
|
2009
|
0.92
|
|
61
|
Artemisinin combination therapy for malaria: beyond good efficacy.
|
Clin Infect Dis
|
2009
|
0.92
|
|
62
|
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.
|
Malar J
|
2015
|
0.91
|
|
63
|
Genetic diversity and population structure of Plasmodium vivax in Central China.
|
Malar J
|
2014
|
0.89
|
|
64
|
An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.
|
PLoS Negl Trop Dis
|
2012
|
0.89
|
|
65
|
A robust design for identification of the Parasite Clearance Estimator.
|
Malar J
|
2013
|
0.87
|
|
66
|
Towards optimal design of anti-malarial pharmacokinetic studies.
|
Malar J
|
2009
|
0.85
|
|
67
|
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy.
|
Malar J
|
2009
|
0.84
|
|
68
|
Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment.
|
J Infect Dis
|
2013
|
0.83
|
|
69
|
Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum.
|
PLoS One
|
2013
|
0.83
|
|
70
|
Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans.
|
J Infect Dis
|
2010
|
0.82
|
|
71
|
Severe congenital malaria acquired in utero.
|
Am J Trop Med Hyg
|
2010
|
0.82
|
|
72
|
Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades.
|
Malar J
|
2011
|
0.82
|
|
73
|
A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults.
|
Malar J
|
2010
|
0.81
|
|
74
|
Maximising the public health benefit of antimalarials.
|
Lancet Infect Dis
|
2010
|
0.79
|
|
75
|
Increased carboxyhemoglobin in adult falciparum malaria is associated with disease severity and mortality.
|
J Infect Dis
|
2013
|
0.79
|
|
76
|
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria.
|
Malar J
|
2009
|
0.79
|
|
77
|
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.
|
Nature
|
2016
|
0.77
|
|
78
|
Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs.
|
AAPS J
|
2014
|
0.77
|
|
79
|
Advances in Parasitology. Preface.
|
Adv Parasitol
|
2012
|
0.75
|
|
80
|
The epidemiology of Plasmodium vivax. Preface.
|
Adv Parasitol
|
2013
|
0.75
|
|
81
|
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.
|
Emerg Infect Dis
|
2017
|
0.75
|